Table 3.
Characteristic | Kidney biopsy not relevant with malignant neoplasms (n = 85) | MGRS-related lesions (n = 43) | MG-unrelated lesions (n = 42) | P |
---|---|---|---|---|
Male | 60 (70.6%) | 26 (60.5%) | 34 (81.0%) | 0.038 |
Age (year) | 55.8 ± 12.4 | 57.7 ± 11.0 | 53.9 ± 13.6 | 0.161 |
Hypertension | 32 (37.6%) | 12 (27.9%) | 20 (47.6%) | 0.061 |
Diabetes | 15 (17.6%) | 4 (9.3%) | 11 (26.2%) | 0.041 |
Hepatitis B | 7 (8.2%) | 3 (7.0%) | 4 (9.5%) | 0.669 |
Serum studies | ||||
Albumin (g/l) | 24.9 ± 8.2 | 23.6 ± 8.3 | 26.2 ± 8.0 | 0.139 |
Creatinine (μmo/l) | 160.1 ± 155.9 | 166.4 ± 175.3 | 153.5 ± 135.0 | 0.705 |
eGFR (ml/min per 1.73 m2) | 63.7 ± 33.9 | 60.0 ± 33.3 | 67.5 ± 34.5 | 0.309 |
eGFR <60 (ml/min per 1.73 m2) | 39 (45.9%) | 24 (55.8%) | 15 (35.7%) | 0.063 |
κ/λ | 1.35 (0.73–1.91) | 0.78 (0.51–1.70) | 1.60 (1.26–2.25) | 0.57 |
Urinary studies | ||||
Urinary protein (g/d) | 5.64 (2.03–7.07) | 5.91 (3.57–7.21) | 3.37 (1.59–7.96) | 0.44 |
Proteinuria >1.5 g/d | 32 (82.1%) | 18 (85.7%) | 14 (77.8%) | 0.52 |
Hematuria | 60 (70.6%) | 30 (69.8%) | 30 (71.4%) | 0.867 |
κ/λ | 1.36 (0.53–2.2) | 0.69 (0.21–1.42) | 1.98 (1.47–3.77) | 0.478 |
Hematologic studies | ||||
Clonal subtype | ||||
Ig isotype | ||||
IgA(+) | 15 (17.6%) | 7 (16.3%) | 8 (19.0%) | 0.738 |
IgG(+) | 24 (28.2%) | 13 (30.2%) | 11 (26.2%) | 0.679 |
IgM(+) | 10 (11.8%) | 3 (7.0%) | 7 (16.7%) | 0.166 |
IgA/IgG/IgM(+) | 0 (0) | 0 (0) | 0 (0) | / |
IgA&IgG&IgM(−) | 36 (42.4%) | 20 (46.5%) | 16 (38.1%) | 0.432 |
Ig light chain | ||||
Kappa(+) | 21 (24.7%) | 7 (16.3%) | 14 (33.3%) | 0.068 |
Lambda(+) | 51 (60.0%) | 29 (67.4%) | 22 (52.4%) | 0.156 |
Kappa&Lambda(+) | 0 (0) | 0 (0) | 0 (0) | / |
Kappa&Lambda(−) | 13 (15.3%) | 7 (16.3%) | 6 (14.3%) | 0.799 |
Received BM biopsy | 49 (57.6%) | 27 (62.8%) | 22 (52.4%) | 0.332 |
Values for continuous variables are described as mean ± SD or median (IQR) depending on the distribution, and for categoric variables described as count (%).